{
    "clinical_study": {
        "@rank": "45133", 
        "arm_group": [
            {
                "arm_group_label": "Evodial", 
                "arm_group_type": "Sham Comparator", 
                "description": "Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)"
            }, 
            {
                "arm_group_label": "Evodial+ Condition B1", 
                "arm_group_type": "Experimental", 
                "description": "Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)"
            }, 
            {
                "arm_group_label": "Evodial+ Condition B2", 
                "arm_group_type": "Experimental", 
                "description": "Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)"
            }, 
            {
                "arm_group_label": "Evodial+ Condition C", 
                "arm_group_type": "Experimental", 
                "description": "Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)"
            }
        ], 
        "brief_summary": {
            "textblock": "Evodial +hemodialyzer consists of an evolution of the existing CE marked Evodial device,\n      with respect to the hemodialyzer membrane removal characteristics. Different membrane\n      prototypes configurations are proposed (3 versions in total), with the objective to modulate\n      the hemodialyzer removal capacities (convective and adsorptive capacities).\n\n      Materials(including heparin grafted specifications) as well as the sterilization process are\n      identical to the Evodial hemodialyzer. Based on available preclinical data , a clinical\n      study is requested to document in vivo the different prototypes removal capacities with\n      respect to middle Molecular Weight (MW) reference toxins such as b2 Microglobulin and\n      collect data with regards to protein loss."
        }, 
        "brief_title": "Evaluation of Evodial Hemodialyzer Selectivity Modifications (Evodial +)", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "End Stage Renal Disease (ESRD)", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Anuric patient (diuresis<300ml) ,\n\n          2. ESRD patient treated for at least 3 months,\n\n          3. Patient treated in HDF post-dilution,\n\n          4. Vascular access functioning properly (Qb > 250 ml/min),\n\n          5. Patient aged 18 years or more,\n\n          6. Written consent to participate in the study (informed consent).\n\n        Exclusion Criteria:\n\n          1. Patient with pre-dialytic albuminemia <3.3 g/dl(Nephelometry assay)\n\n          2. Patient with known allergy to heparin or type II heparininduced thrombocytopenia (HIT\n             type II);\n\n          3. Patient under guardianship;\n\n          4. Women pregnant or breast feeding;\n\n          5. Patient included in other studies that could interfere with the goals of the current\n             study.\n\n          6. Patient that are not affiliated to the health system(beneficiary or dependent).\n\n          7. Patient with positive serology (HIV, Hepatitis)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01783626", 
            "org_study_id": "1498"
        }, 
        "intervention": [
            {
                "arm_group_label": "Evodial", 
                "intervention_name": "Evodial", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Evodial+ Condition B1", 
                "intervention_name": "Evodial+ Condition B1", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Evodial+ Condition B2", 
                "intervention_name": "Evodial+ Condition B2", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Evodial+ Condition C", 
                "intervention_name": "Evodial+ Condition C", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cherbourg-Octeville", 
                    "country": "France", 
                    "zip": "50102"
                }, 
                "name": "H\u00f4pital Louis-Pasteur (Cherbourg-Octeville)"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "4", 
        "official_title": "Evaluation of Evodial Hemodialyzer Selectivity Modifications (Evodial +) - A Prospective, Monocenter, Open and Non-randomized Pilot Study", 
        "overall_official": {
            "affiliation": "Gambro Industries", 
            "last_name": "Nathalie Loughraieb", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Efficacy: Beta 2 Microglobulin elimination", 
            "safety_issue": "No", 
            "time_frame": "Change from T0 (dialysis start) at T4 hours (dialysis stop)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01783626"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Efficacy: -Elimination of Myoglobin,alpha 1 Microglobulin, alpha amylase and Factor D", 
                "safety_issue": "No", 
                "time_frame": "Change from T0 (dialysis start) at T 4hours (dialysis stop)"
            }, 
            {
                "measure": "Efficacy:Profile of ultrafiltrated proteins", 
                "safety_issue": "No", 
                "time_frame": "at T4 hours"
            }, 
            {
                "measure": "Safety: Follow-up of all AEs/SAEs", 
                "safety_issue": "Yes", 
                "time_frame": "during the study period"
            }, 
            {
                "measure": "Safety: Measurement of Albumin loss", 
                "safety_issue": "Yes", 
                "time_frame": "At T4 hours"
            }, 
            {
                "measure": "Efficacy: Cumulative Purified volume (Kt)", 
                "safety_issue": "No", 
                "time_frame": "At T4 hours"
            }, 
            {
                "measure": "Safety: Total protein", 
                "safety_issue": "Yes", 
                "time_frame": "Change from T0 and T4 hours"
            }
        ], 
        "source": "Gambro Lundia AB", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gambro Lundia AB", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}